Financial & competing interests disclosure
CI Webster is an employee of MedImmune, an orginisation with financial interest in the subject matter of this manuscript, and therefore has a potential conflict of interest. DB Stanmirovic is employed by the Government of Canada (National Research Council of Canada) who have several Sponsored Research Agreements with industrial partners to develop blood–brain–barrier carriers, including FC5. DBS does not have financial or managerial interests in these companies. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.